Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.38 EUR | -1.24% |
|
-0.86% | +13.41% |
06-12 | Spanish stocks - Factors to watch on June 12 | RE |
06-12 | Grifols to Finalize Delisting Offer for Biotest | MT |
Capitalization | 6.39B 7.36B 6.01B 5.46B 10.07B 636B 11.29B 70.6B 27.29B 291B 27.62B 27.03B 1,064B | P/E ratio 2025 * |
16.5x | P/E ratio 2026 * | 11.4x |
---|---|---|---|---|---|
Enterprise value | 15.43B 17.78B 14.52B 13.19B 24.32B 1,536B 27.26B 171B 65.89B 703B 66.7B 65.28B 2,570B | EV / Sales 2025 * |
2.02x | EV / Sales 2026 * | 1.83x |
Free-Float |
79.4% | Yield 2025 * |
-
| Yield 2026 * | 1.86% |
More valuation ratios
* Estimated data
More news
Last Transcript: Grifols, S.A.
More recommendations
More press releases
More news
1 day | -1.24% | ||
1 week | -1.33% | ||
Current month | +9.56% | ||
1 month | +15.28% | ||
3 months | +9.14% | ||
6 months | +6.19% | ||
Current year | +13.41% |
1 week | 10.08 | ![]() | 10.74 |
1 month | 8.95 | ![]() | 10.74 |
Current year | 7.32 | ![]() | 11.27 |
1 year | 7.32 | ![]() | 11.35 |
3 years | 6.36 | ![]() | 19.58 |
5 years | 6.36 | ![]() | 28.84 |
10 years | 6.36 | ![]() | 34.31 |
Manager | Title | Age | Since |
---|---|---|---|
Nacho Abia
CEO | Chief Executive Officer | 56 | 31/03/2024 |
Jörg Schüttrumpf
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/08/2023 |
Corporate Officer/Principal | 69 | 30/04/2016 |
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 12/04/2000 | |
Director/Board Member | 62 | 23/05/2015 | |
Director/Board Member | 49 | 29/05/2016 |
Name | Weight | AuM | 1st Jan change | |
---|---|---|---|---|
0.98% | 126 M€ | +20.58% | - | |
0.21% | 1,022 M€ | +19.35% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-1.24% | -1.33% | +13.44% | -42.04% | 7.44B | ||
+1.12% | -0.88% | -16.22% | -5.48% | 75.35B | ||
-0.59% | +0.40% | +36.41% | +20.67% | 52.44B | ||
-1.90% | -5.86% | +13.08% | +97.64% | 34.64B | ||
+0.01% | -4.90% | -43.42% | -37.28% | 18.54B | ||
+1.95% | -3.08% | +106.57% | +192.19% | 16.22B | ||
-0.63% | +0.51% | +47.66% | +735.98% | 15.5B | ||
-0.04% | -.--% | +74.71% | +140.03% | 14.02B | ||
-0.83% | -0.84% | +11.12% | -4.21% | 13.32B | ||
-1.93% | -6.90% | -5.74% | -41.10% | 11.29B | ||
Average | -0.41% | -2.33% | +23.76% | +105.64% | 25.88B | |
Weighted average by Cap. | -0.13% | -2.46% | +15.59% | +73.49% |
2025 * | 2026 * | |
---|---|---|
Net sales | 7.65B 8.81B 7.2B 6.54B 12.06B 762B 13.52B 84.55B 32.68B 348B 33.07B 32.37B 1,275B | 8.2B 9.45B 7.72B 7.01B 12.92B 816B 14.48B 90.61B 35.02B 373B 35.44B 34.69B 1,366B |
Net income | 417M 480M 392M 356M 657M 41.51B 736M 4.61B 1.78B 18.99B 1.8B 1.76B 69.45B | 605M 697M 569M 517M 954M 60.22B 1.07B 6.68B 2.58B 27.55B 2.61B 2.56B 101B |
Net Debt | 9.04B 10.41B 8.51B 7.73B 14.25B 900B 15.97B 99.9B 38.61B 412B 39.08B 38.25B 1,506B | 8.58B 9.89B 8.08B 7.34B 13.53B 854B 15.16B 94.83B 36.65B 391B 37.09B 36.31B 1,429B |
More financial data
* Estimated data
Employees
23,800
Sector
Pharmaceuticals
Calendar
Date | Price | Change | Volume |
---|---|---|---|
18/06/25 | 10.38 € | -1.24% | 2,173,572 |
17/06/25 | 10.50 € | -1.18% | 1,672,322 |
16/06/25 | 10.63 € | +4.27% | 2,625,849 |
13/06/25 | 10.20 € | -3.23% | 2,715,257 |
12/06/25 | 10.54 € | +0.67% | 1,707,379 |
Delayed Quote BME, June 18, 2025 at 04:35 pm
More quotesSell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
10.38EUR
Average target price
15.96EUR
Spread / Average Target
+53.85%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GRF Stock
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition